N2OFF Shareholders Approve Acquisition of SciSparc’s MitoCareX Subsidiary, Paving Way for Completion in October 2025

Reuters09-30

N2OFF Shareholders Approve Acquisition of SciSparc's MitoCareX Subsidiary, Paving Way for Completion in October 2025

SciSparc Ltd. announced that shareholders of N2OFF, Inc. have approved the proposed acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd. The approval was granted at a special meeting of N2OFF stockholders held on September 25, 2025, clearing a key path toward completing the transaction. Under the agreement, N2OFF will acquire full ownership of MitoCareX, a drug discovery company targeting resistant cancers such as pancreatic and non-small cell lung cancer. The deal, which includes both cash and stock considerations, is expected to close in the first half of October 2025, pending satisfaction of remaining closing conditions. Following the transaction, MitoCareX will become a wholly owned subsidiary of N2OFF and will receive financial support for its operations, including an initial $1 million investment. SciSparc disclosed the update.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536966-en) on September 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2571067357?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 04:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571067357","market":"fut","top_or_hot":-1,"title":"N2OFF Shareholders Approve Acquisition of SciSparc’s MitoCareX Subsidiary, Paving Way for Completion in October 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      N2OFF Shareholders Approve Acquisition of SciSparc's MitoCareX Subsidiary, Paving Way for Completion in October 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRC\">SciSparc Ltd.</a> announced that shareholders of <a href=\"https://laohu8.com/S/NITO\">N2OFF, Inc</a>. have approved the proposed acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd. The approval was granted at a special meeting of N2OFF stockholders held on September 25, 2025, clearing a key path toward completing the transaction. Under the agreement, N2OFF will acquire full ownership of MitoCareX, a drug discovery company targeting resistant cancers such as pancreatic and non-small cell lung cancer. The deal, which includes both cash and stock considerations, is expected to close in the first half of October 2025, pending satisfaction of remaining closing conditions. Following the transaction, MitoCareX will become a wholly owned subsidiary of N2OFF and will receive financial support for its operations, including an initial $1 million investment. SciSparc disclosed the update.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536966-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>N2OFF Shareholders Approve Acquisition of SciSparc’s MitoCareX Subsidiary, Paving Way for Completion in October 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nN2OFF Shareholders Approve Acquisition of SciSparc’s MitoCareX Subsidiary, Paving Way for Completion in October 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 04:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      N2OFF Shareholders Approve Acquisition of SciSparc's MitoCareX Subsidiary, Paving Way for Completion in October 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRC\">SciSparc Ltd.</a> announced that shareholders of <a href=\"https://laohu8.com/S/NITO\">N2OFF, Inc</a>. have approved the proposed acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd. The approval was granted at a special meeting of N2OFF stockholders held on September 25, 2025, clearing a key path toward completing the transaction. Under the agreement, N2OFF will acquire full ownership of MitoCareX, a drug discovery company targeting resistant cancers such as pancreatic and non-small cell lung cancer. The deal, which includes both cash and stock considerations, is expected to close in the first half of October 2025, pending satisfaction of remaining closing conditions. Following the transaction, MitoCareX will become a wholly owned subsidiary of N2OFF and will receive financial support for its operations, including an initial $1 million investment. SciSparc disclosed the update.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536966-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4093","symbol_name":"化肥与农用药剂","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL2ytt9Z:1","article_id":"2571067357","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571067357","pubTimestamp":1759176192,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SciSparc Ltd. announced that shareholders of N2OFF, Inc. have approved the proposed acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd. The approval was granted at a special meeting of N2OFF stockholders held on September 25, 2025, clearing a key path toward completing the transaction. Under the agreement, N2OFF will acquire full ownership of MitoCareX, a drug discovery company targeting resistant cancers such as pancreatic and non-small cell lung cancer. The deal, which includes both cash and stock considerations, is expected to close in the first half of October 2025, pending satisfaction of remaining closing conditions. Following the transaction, MitoCareX will become a wholly owned subsidiary of N2OFF and will receive financial support for its operations, including an initial $1 million investment. SciSparc disclosed the update.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4093":"化肥与农用药剂","SPRC":"SciSparc Ltd.","BK4539":"次新股","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","NITO":"N2OFF, Inc","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"N2OFF股东批准收购SciSparc的MitoCareX子公司，为2025年10月完成铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NITO":0.9,"SPRC":0.9},"content_text":"N2OFF Shareholders Approve Acquisition of SciSparc's MitoCareX Subsidiary, Paving Way for Completion in October 2025\n    \n\nSciSparc Ltd. announced that shareholders of N2OFF, Inc. have approved the proposed acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd. The approval was granted at a special meeting of N2OFF stockholders held on September 25, 2025, clearing a key path toward completing the transaction. Under the agreement, N2OFF will acquire full ownership of MitoCareX, a drug discovery company targeting resistant cancers such as pancreatic and non-small cell lung cancer. The deal, which includes both cash and stock considerations, is expected to close in the first half of October 2025, pending satisfaction of remaining closing conditions. Following the transaction, MitoCareX will become a wholly owned subsidiary of N2OFF and will receive financial support for its operations, including an initial $1 million investment. SciSparc disclosed the update.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536966-en) on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571067357","isCrawlerRequest":true}